Sweden · Delayed Price · Currency is SEK Biosergen AB Statistics
Total Valuation
Biosergen AB has a market cap or net worth of SEK 93.93 million. The enterprise value is 71.22 million.
| Market Cap | 93.93M |
| Enterprise Value | 71.22M |
Important Dates
The next estimated earnings date is Tuesday, March 31, 2026.
| Earnings Date | Mar 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biosergen AB has 2.35 million shares outstanding. The number of shares has increased by 287.06% in one year.
| Current Share Class | 2.35M |
| Shares Outstanding | 2.35M |
| Shares Change (YoY) | +287.06% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 42.05% |
| Float | 850,731 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 4.64 |
| P/TBV Ratio | 4.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.33 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.85
| Current Ratio | 4.85 |
| Quick Ratio | 4.85 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -191.42% and return on invested capital (ROIC) is -120.02%.
| Return on Equity (ROE) | -191.42% |
| Return on Assets (ROA) | -95.71% |
| Return on Invested Capital (ROIC) | -120.02% |
| Return on Capital Employed (ROCE) | -151.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -30.59M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.08% in the last 52 weeks. The beta is 0.29, so Biosergen AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -23.08% |
| 50-Day Moving Average | 44.57 |
| 200-Day Moving Average | 46.89 |
| Relative Strength Index (RSI) | 41.44 |
| Average Volume (20 Days) | 1,230 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -30.69M |
| Pretax Income | -30.59M |
| Net Income | -30.59M |
| EBITDA | n/a |
| EBIT | -30.69M |
| Earnings Per Share (EPS) | -8.83 |
Balance Sheet
The company has 22.71 million in cash and n/a in debt, with a net cash position of 22.71 million or 9.67 per share.
| Cash & Cash Equivalents | 22.71M |
| Total Debt | n/a |
| Net Cash | 22.71M |
| Net Cash Per Share | 9.67 |
| Equity (Book Value) | 20.26M |
| Book Value Per Share | 8.63 |
| Working Capital | 20.26M |
Cash Flow
| Operating Cash Flow | -20.15M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biosergen AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -287.06% |
| Shareholder Yield | -287.06% |
| Earnings Yield | -32.57% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 1, 2025. It was a reverse split with a ratio of 0.01.
| Last Split Date | Dec 1, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |